http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019144944-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f57b0c0a31846d32c96c6b72bdbf2260
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-00
filingDate 2018-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b163faf225cf4721bc7a517b2ea86163
publicationDate 2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2019144944-A1
titleOfInvention Treatment and diagnosis of epigenetic disorders and conditions
abstract A method identifies a trinucleotide expansion disorder in a mammalian subject. The method includes screening for a change relative to a healthy control in the extent of epigenetic modification within two or more of an intron, an intron/exon boundary, and/or a splicing region. A change in extent of epigenetic modification relative to the control is indicative of the presence or severity of the trinucleotide expansion disorder or a propensity to develop such a disorder. The intron, intron/exon boundary and/or splicing region can be Fragile X-related Epigenetic Element 3 in FMR1, intron 2 of FMR1, or genomic FREE2 region as a whole or specific fragments of FREE2 including FREE2 (D), FREE2 (E) or FREE3. A method detects methylation in Fragile X-related Epigenetic Element 2(D) (FREE2(D)) in genomic DNA of a human subject and a computer program assesses progression of a pathological condition associated with the FMR locus in a subject
priorityDate 2010-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1134
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13013858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226550874
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20055127
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393686
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409524
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21715388
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID168473
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135444779
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226576771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395976
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398658
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60961
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226434160

Total number of triples: 38.